IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection
Open Access
- 1 December 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 99 (12), 2953-2956
- https://doi.org/10.1007/s00277-020-04160-w
Abstract
No abstract availableKeywords
Funding Information
- CRIS foundation for cancer research
- grant from Fondo de investigaciones sanitarias of the Spanish Health System (COV20/00181)
This publication has 7 references indexed in Scilit:
- Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyThe Lancet Rheumatology, 2020
- Cytokine release syndrome in severe COVID-19Science, 2020
- Immunotherapies for COVID-19: lessons learned from sepsisThe Lancet Respiratory Medicine, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- Overview of the IL‐1 family in innate inflammation and acquired immunityImmunological Reviews, 2017
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation SyndromeCritical Care Medicine, 2016
- Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed TherapiesAnnual Review of Medicine, 2015